Compare Adaptive Biotechnologies Corp (ADPT) vs Annaly Capital Management, Inc. (NLY) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Annaly Capital Management (NLY) trades at $22.69, up 0.58% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 7.42, ROE of 15.61%, and consistent earnings beats in recent quarters. Recent dividend increases to $0.75 per share and positive analyst coverage highlight income appeal. The company maintains solid liquidity despite significant investing outflows.

NLY presents a compelling income opportunity with a 13.2% dividend yield and analyst consensus target of $24.40. However, risks include interest rate sensitivity, high leverage (debt-to-asset ratio of 23.55), and volatile cash flow patterns. The stock offers 7.5% upside potential but requires monitoring of Federal Reserve policy impacts on mortgage REITs.